{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:49:20Z","timestamp":1783003760387,"version":"3.54.5"},"update-to":[{"DOI":"10.1002\/14651858.cd005224","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2007,10,17]],"date-time":"2007-10-17T00:00:00Z","timestamp":1192579200000}}],"reference-count":56,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd005224.pub2","type":"journal-article","created":{"date-parts":[[2007,10,10]],"date-time":"2007-10-10T12:19:30Z","timestamp":1192018770000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Immunosuppressive agents for myasthenia gravis"],"prefix":"10.1002","volume":"2010","author":[{"given":"Ian K","family":"Hart","sequence":"first","affiliation":[{"name":"The Walton Centre for Neurology and Neurosurgery; University Division of Neuroscience; Lower Lane Liverpool UK L9 7LJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivakumar","family":"Sathasivam","sequence":"additional","affiliation":[{"name":"The Walton Centre for Neurology and Neurosurgery; Neurology Department; Lower Lane Liverpool UK L9 7LJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Sharshar","sequence":"additional","affiliation":[{"name":"H\u00f4pital Raymond Poincar\u00e9; Service de R\u00e9animation M\u00e9dicale; 104 Boulevard Raymond Poincar\u00e9 Garches Ile de France France 92380"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,10,17]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD005224.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mus.10133","article-title":"Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis","volume":"26","author":"Feo","year":"2002","journal-title":"Muscle and Nerve"},{"issue":"11","key":"10.1002\/14651858.CD005224.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/jnnp.56.11.1157","article-title":"A randomised clinical trial comparing prednisolone and azathioprine in myasthenia gravis. Results of a second interim analysis","volume":"56","author":"Myasthenia Gravis Clinical Study Group","year":"1993","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD005224.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1196\/annals.1254.064","article-title":"Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study","volume":"998","author":"Meriggioli","year":"2003","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"3","key":"10.1002\/14651858.CD005224.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000085833","article-title":"Efficacy of low-dose FK506 in the treatment of myasthenia gravis - a randomized pilot study","volume":"53","author":"Nagane","year":"2005","journal-title":"European Neurology"},{"issue":"6","key":"10.1002\/14651858.CD005224.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD005224.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM198703193161205","article-title":"Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis","volume":"316","author":"Tindall","year":"1987","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005224.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","article-title":"A clinical therapeutic trial of cyclosporine in myasthenia gravis","volume":"681","author":"Tindall","year":"1993","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"1","key":"10.1002\/14651858.CD005224.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-510X(97)05370-7","article-title":"Randomized trial of azathioprine or prednisolone for initial immunosuppressive treatment of myasthenia gravis","volume":"150","author":"Bromberg","year":"1997","journal-title":"Journal of Neurological Sciences"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005224.pub2-BIB0009|cit9","first-page":"165","article-title":"Ciclosporin A vs. azathioprine in the treatment of myasthenia gravis: final results of a randomised control double-blind clinical trial","volume":"37","author":"Schalke","year":"1990","journal-title":"Jikeikai Medical Journal"},{"key":"10.1002\/14651858.CD005224.pub2-BIB0010|cit10","unstructured":"Sanders DB Ross M Goldstein J Pulley M Meriggioli M Barohn R Trial of mycophenolate mofetil in myasthenia gravis www.clinicaltrials.gov"},{"key":"10.1002\/14651858.CD005224.pub2-BIB0011|cit11","unstructured":"Sanders DB Hart IK Mantegazza R Shukla SS Siddiqi ZA Results of a large, international, double-blind, placebo-controlled phase III trial of mycophenolate mofetil as a steroid-sparing adjunct in the treatment of myasthenia gravis Unpublished article"},{"key":"10.1002\/14651858.CD005224.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score","volume":"841","author":"Barohn","year":"1998","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"10","key":"10.1002\/14651858.CD005224.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1212\/WNL.33.10.1316","article-title":"Myasthenia gravis: Long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity","volume":"33","author":"Besinger","year":"1983","journal-title":"Neurology"},{"issue":"9","key":"10.1002\/14651858.CD005224.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s004150050141","article-title":"Long-term cyclosporine treatment in a group of severe myasthenia gravis patients","volume":"244","author":"Bonifati","year":"1997","journal-title":"Journal of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD005224.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/WNL.56.1.94","article-title":"Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases","volume":"56","author":"Chaudhry","year":"2001","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD005224.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1212\/WNL.55.3.448","article-title":"Retrospective analysis of the use of cyclosporine in myasthenia gravis","volume":"55","author":"Ciafaloni","year":"2000","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD005224.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1212\/WNL.56.1.97","article-title":"Mycophenolate mofetil for myasthenia gravis: an open-label pilot study","volume":"56","author":"Ciafaloni","year":"2001","journal-title":"Neurology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD005224.pub2-BIB0018|cit18","first-page":"A137","article-title":"Mycophenolate mofetil (MyM) is safe and well tolerated in myasthenia gravis (MG)","volume":"54","author":"Cos","year":"2000","journal-title":"Neurology"},{"issue":"25","key":"10.1002\/14651858.CD005224.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199406233302507","article-title":"Myasthenia gravis","volume":"330","author":"Drachman","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005224.pub2-BIB0020|cit20","volume-title":"Meyler's Side Effects of Drugs","author":"Dukes","year":"2000"},{"issue":"4","key":"10.1002\/14651858.CD005224.pub2-BIB0021|cit21","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002275","article-title":"Plasma exchange for myasthenia gravis","author":"Gajdos","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD005224.pub2-BIB0022|cit22","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002277","article-title":"Intravenous immunoglobulin for myasthenia gravis","author":"Gajdos","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3 Suppl 4","key":"10.1002\/14651858.CD005224.pub2-BIB0023|cit23","first-page":"211","article-title":"Results of a one-year open trial of cyclosporine in ten patients with severe myasthenia gravis","volume":"20","author":"Goulon","year":"1988","journal-title":"Transplantation Proceedings"},{"key":"10.1002\/14651858.CD005224.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1749-6632.1981.tb33764.x","article-title":"The natural course of myasthenia gravis and effect of therapeutic measures","volume":"377","author":"Grob","year":"1981","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"9","key":"10.1002\/14651858.CD005224.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1046\/j.1525-1594.2002.07070.x","article-title":"Malignant tumors after renal transplantation","volume":"26","author":"Haberal","year":"2002","journal-title":"Artificial organs"},{"issue":"9","key":"10.1002\/14651858.CD005224.pub2-BIB0026|cit26","first-page":"765","article-title":"High-dose immunosuppressive therapy in generalised myasthenia gravis - a 2-year follow-up study","volume":"91","author":"Heckmann","year":"2001","journal-title":"South African Medical Journal"},{"issue":"3","key":"10.1002\/14651858.CD005224.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ana.410170304","article-title":"Myasthenia gravis: Reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine","volume":"17","author":"Hohlfeld","year":"1985","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD005224.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1212\/WNL.38.2.258","article-title":"Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis","volume":"38","author":"Hohlfeld","year":"1988","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD005224.pub2-BIB0029|cit29","doi-asserted-by":"crossref","DOI":"10.1016\/B978-012125831-3\/50289-6","volume-title":"Therapy of myasthenia gravis and myasthenic syndromes","author":"Hohlfeld","year":"2003"},{"key":"10.1002\/14651858.CD005224.pub2-BIB0030|cit30","doi-asserted-by":"crossref","unstructured":"Imao T Ichimaru N Takahara S Kokado Y Okumi M Imamura R Namba Y Isaka Y Nonomura N Okuyama A Risk factors for malignancy in Japanese renal transplant recipients Cancer 2007 Epub ahead of print","DOI":"10.1002\/cncr.22636"},{"issue":"1","key":"10.1002\/14651858.CD005224.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis. Recommendations for clinical research standards","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"issue":"8","key":"10.1002\/14651858.CD005224.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1185\/030079904125004385","article-title":"Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis","volume":"20","author":"Kawaguchi","year":"2004","journal-title":"Current Medical Research and Opinion"},{"issue":"11","key":"10.1002\/14651858.CD005224.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1212\/WNL.36.1.35","article-title":"Azathioprine toxicity in neuromuscular disease","volume":"36","author":"Kissel","year":"1986","journal-title":"Neurology"},{"issue":"10","key":"10.1002\/14651858.CD005224.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1307-11, commen","DOI":"10.1136\/ard.2003.019125","article-title":"Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide","volume":"63","author":"Knight","year":"2004","journal-title":"Annals of the rheumatic diseases"},{"issue":"5","key":"10.1002\/14651858.CD005224.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/mus.10472","article-title":"Clinical study of FK506 in patients with myasthenia gravis","volume":"28","author":"Konishi","year":"2003","journal-title":"Muscle & Nerve"},{"issue":"3","key":"10.1002\/14651858.CD005224.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/jnnp.2004.042176","article-title":"Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus)","volume":"76","author":"Konishi","year":"2005","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD005224.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0960-8966(91)90005-D","article-title":"Azathioprine in myasthenia gravis: observations in 41 patients and a review of literature","volume":"1","author":"Kuks","year":"1991","journal-title":"Neuromuscular Disorders"},{"issue":"4","key":"10.1002\/14651858.CD005224.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-0404.2005.00378.x","article-title":"Cyclosporine in the treatment of myasthenia gravis","volume":"111","author":"Lavrnic","year":"2005","journal-title":"Acta Neurologica Scandinavica"},{"issue":"8","key":"10.1002\/14651858.CD005224.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF00314245","article-title":"Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis","volume":"235","author":"Mantegazza","year":"1988","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD005224.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1749-6632.1976.tb47724.x","article-title":"Effects of some immunosuppressive procedures in myasthenia gravis","volume":"274","author":"Matell","year":"1976","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"10","key":"10.1002\/14651858.CD005224.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.WNL.0000094122.88929.0B","article-title":"Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability","volume":"61","author":"Meriggioli","year":"2003","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD005224.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/00004691-200309000-00011","article-title":"Single fiber EMG as an outcome measure in myasthenia gravis: results from a double-blind placebo-controlled trial","volume":"20","author":"Meriggioli","year":"2003","journal-title":"Journal of Clinical Neurophysiology"},{"issue":"6","key":"10.1002\/14651858.CD005224.pub2-BIB0043|cit43","first-page":"321","article-title":"The treatment of severe myasthenia gravis with immunosuppressive agents","volume":"2","author":"Mertens","year":"1969","journal-title":"European Neurology"},{"key":"10.1002\/14651858.CD005224.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1749-6632.1981.tb33767.x","article-title":"Effect of immunosuppressive drugs (azathioprine)","volume":"377","author":"Mertens","year":"1981","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"6","key":"10.1002\/14651858.CD005224.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/ana.410240619","article-title":"Myasthenia gravis: discontinuation of long-term azathioprine","volume":"24","author":"Michels","year":"1988","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD005224.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.1749-6632.1981.tb33766.x","article-title":"Observations of the natural history of myasthenia gravis and the effect of thymectomy","volume":"377","author":"Oosterhuis","year":"1981","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD005224.pub2-BIB0047|cit47","first-page":"75","article-title":"Long-term effects of treatment in 374 patients with myasthenia gravis","volume":"25","author":"Oosterhuis","year":"1988","journal-title":"Monographs in Allergy"},{"issue":"1","key":"10.1002\/14651858.CD005224.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1212\/WNL.31.1.32","article-title":"Stable remissions in myasthenia gravis","volume":"31","author":"Perez","year":"1981","journal-title":"Neurology"},{"issue":"9","key":"10.1002\/14651858.CD005224.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1212\/01.WNL.0000160392.32894.6D","article-title":"Long-term results of tacrolimus in cyclosporine- and prednisolone-dependant myasthenia gravis","volume":"64","author":"Ponseti","year":"2005","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD005224.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1212\/01.WNL.0000098887.24618.A0","article-title":"Treatment of autoimmune myasthenia gravis","volume":"61","author":"Richman","year":"2003","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD005224.pub2-BIB0051|cit51","article-title":"Corticosteroids for myasthenia gravis","author":"Schneider-Gold","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD005224.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1468-1331.2006.01476.x","article-title":"Guidelines for the treatment of autoimmune neuromuscular transmission disorders.","volume":"13","author":"Skeie","year":"2006","journal-title":"European Journal of Neurology"},{"issue":"12","key":"10.1002\/14651858.CD005224.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1136\/jnnp.48.12.1246","article-title":"Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays","volume":"48","author":"Vincent","year":"1985","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"9274","key":"10.1002\/14651858.CD005224.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/S0140-6736(00)05186-2","article-title":"Myasthenia gravis","volume":"357","author":"Vincent","year":"2001","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD005224.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1474-4422(03)00306-5","article-title":"Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets","volume":"2","author":"Vincent","year":"2003","journal-title":"Lancet Neurology"},{"issue":"6","key":"10.1002\/14651858.CD005224.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/ana.410150615","article-title":"Azathioprine in the treatment of myasthenia gravis","volume":"15","author":"Witte","year":"1984","journal-title":"Annals of Neurology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD005224.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:46:55Z","timestamp":1778860015000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD005224.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Neuromuscular Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2007,10,17]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005224.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,17]]}}}